IDEAYA Biosciences Inc. (IDYA)
NASDAQ: IDYAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
IDYA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.50B
- EPS (TTM)
- -$1.94
- Dividend yield
- None
- 52-week range
- 26.05 – 42.68
- Day range
- 36.00 – 36.97
- Volume / Avg
- 552.06K / 799.78K
- Beta
- —
- Shares outstanding
- 96.49M
- Next earnings
- Nov 3, 2026
52-week range
IDYA stock today
IDEAYA Biosciences (IDYA) closed at $36.26 on Oct 7, down 1.01% (-$0.37), versus the S&P 500's 0.22% decline. Shares are 15.0% below their 52-week high of $42.68, set on Aug 25, 2026 and 39.2% above the 52-week low of $26.05, in the middle of the past year's range. IDYA is up 4.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 34.7%.
IDEAYA Biosciences has posted a net loss over the last twelve months (EPS of -$1.94), so its P/E ratio is not meaningful. IDEAYA Biosciences's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About IDEAYA Biosciences
Company profileIDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Yujiro S. Hata
- Headquarters
- South San Francisco, CA
- Employees
- 145
- IPO year
- 2019
- Website
- ideayabio.com
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$52.75+45.48%
- Strong buy 3
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-1.28
IDYA news
All IDYA newsIDEAYA Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XENEXenon Pharmaceuticals Inc. | 36.41 | -0.44% | $3.53B | vs IDYA |
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs IDYA |
| OGNOrganon & Co. | 13.79 | +0.36% | $3.62B | vs IDYA |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs IDYA |
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs IDYA |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs IDYA |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs IDYA |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs IDYA |
Indexes, lists and sector
IDEAYA Biosciences stock FAQ
What is IDEAYA Biosciences's stock price today?
IDYA last traded at $36.26 as of Oct 7, 4:00 PM EDT, down 1.01% on the day. Prices are delayed at least 15 minutes.
When is IDEAYA Biosciences's next earnings date?
IDEAYA Biosciences is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-1.28.
Who is IDEAYA Biosciences's CEO?
Mr. Yujiro S. Hata is the chief executive officer of IDEAYA Biosciences Inc., which has about 145 employees.
What is the IDYA 52-week high?
The 52-week high for IDYA is $42.68 and the 52-week low is $26.05. The stock is currently 15.0% below its high.